Vertex Pharmaceuticals (VRTX) Invested Capital (2009 - 2024)

Vertex Pharmaceuticals' Invested Capital history runs 14 years deep, the most recent figure standing at $118.0 million for Q4 2024.

• On a quarterly basis, Invested Capital fell 72.35% year-over-year to $118.0 million in Q4 2024; TTM through Sep 2025 was $118.0 million, a 78.38% decrease from a year earlier, with the FY2024 full-year figure at $118.0 million, down 72.35% from the prior year.
• Invested Capital fell to $118.0 million in Q4 2024 per VRTX's latest filing, from $119.1 million in the prior quarter.
• Across five years, Invested Capital topped out at $581.5 million in Q4 2020 and bottomed at $118.0 million in Q4 2024.
• The 5-year median for Invested Capital is $449.2 million (2022), against an average of $378.9 million.
• Across the five-year window, Invested Capital grew 0.72% in 2020 and tumbled 72.35% in 2024, its largest moves.
• Year by year, Invested Capital stood at $581.5 million in 2020, then fell by 4.26% to $556.7 million in 2021, then slipped by 15.29% to $471.6 million in 2022, then dropped by 9.52% to $426.7 million in 2023, then tumbled by 72.35% to $118.0 million in 2024.
• Per Business Quant, the three latest VRTX Invested Capital figures stand at $118.0 million (Q4 2024), $119.1 million (Q3 2024), and $426.7 million (Q4 2023).